Your session is about to expire
← Back to Search
Virus Therapy
TAVO412 for Cancer (TAVO412 Trial)
Phase 1
Recruiting
Led By Deborah Doroshow, MD
Research Sponsored by Tavotek Biotherapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 12 months
Awards & highlights
TAVO412 Trial Summary
This trial will test the safety and effectiveness of a new drug, TAVO412, for advanced/metastatic solid tumors in two parts. Part 1 will determine the best dose and Part 2 will assess safety, effectiveness, and other measures for gastric cancer and NSCLC.
Who is the study for?
This trial is for adults with advanced or metastatic solid tumors, including gastric cancer and NSCLC, who have not responded to standard treatments. Participants must be over 18, have measurable disease progression, and an ECOG status of 0 or 1. Women of childbearing potential must test negative for pregnancy and agree to contraception measures.Check my eligibility
What is being tested?
TAVO412's safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy are being tested in two parts: first to determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D), then further evaluation in new subjects with specific cancers that didn't respond to standard care.See study design
What are the potential side effects?
While the specific side effects of TAVO412 are not listed here as it is a Phase I study primarily assessing safety and tolerability; generally such early-phase trials may involve risks like infusion reactions, fatigue, nausea, blood count changes among others.
TAVO412 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety and Tolerability of TAVO412 according to Adverse Events and Number of Participants With Dose Limiting Toxicity (DLT) using National Cancer Institute CTCAE v5.0
Secondary outcome measures
Area Under the Serum Concentration-Time Curve From 0-1 (AUC[t0-t1])
Duration of Disease Control (CR, PR, and SD)
Duration of Response (DOR)
+5 moreTAVO412 Trial Design
7Treatment groups
Experimental Treatment
Group I: Part 2 CohortsExperimental Treatment1 Intervention
IV infusion of TAVO412
Group II: Part 1 Cohort 5Experimental Treatment1 Intervention
IV infusion of TAVO412
Group III: Part 1 Cohort 4Experimental Treatment1 Intervention
IV infusion of TAVO412
Group IV: Part 1 Cohort 3Experimental Treatment1 Intervention
IV infusion of TAVO412
Group V: Part 1 Cohort 2Experimental Treatment1 Intervention
IV infusion of TAVO412
Group VI: Part 1 Cohort 1Experimental Treatment1 Intervention
IV infusion of TAVO412
Group VII: Part 1 Cohort 0Experimental Treatment1 Intervention
IV infusion of TAVO412
Find a Location
Who is running the clinical trial?
Tavotek BiotherapeuticsLead Sponsor
3 Previous Clinical Trials
92 Total Patients Enrolled
Deborah Doroshow, MDPrincipal InvestigatorMOUNT SINAI HOSPITAL
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have colorectal cancer and have been treated with specific chemotherapy and, if applicable, targeted therapy.I do not have an active infection needing treatment.I haven't had any cancer except for skin cancer in the last 5 years.My kidneys work well enough (creatinine clearance ≥ 30 mL/min).I am 18 years old or older.I haven't received blood products or colony stimulating factors in the last 14 days.I am fully active or can carry out light work.My kidneys are not functioning well (creatinine clearance < 30 mL/min).I have active brain metastases or carcinomatous meningitis.I haven't taken any cancer drugs or experimental medications recently.I still have side effects from previous treatments that are not mild.I have an autoimmune disease that needed treatment.I agree to give extra blood or tissue samples for research.My cancer has come back or hasn't responded to treatment and can't be surgically removed with the aim of curing it.My cancer can be measured and has grown in previously treated areas.I agree to use birth control during and for 60 days after the study.My hepatitis C virus levels are undetectable while on treatment.I've been vaccinated for hepatitis B and only have antibodies showing I was exposed.I have liver issues but can tolerate normal medication doses.I haven't had AIDS-related infections in the last year.I have not had serious heart issues or surgeries in the last 6 months.I have had a condition where my lymphocytes grow abnormally.I am a woman who can have children and have a negative pregnancy test.I agree to use birth control methods for 90 days after my last dose.I have had or currently have another type of cancer besides the one being treated.I have not received a live vaccine in the last 30 days.My TNBC has worsened despite treatment with specific drugs.I am willing to have tumor biopsies before and during treatment.I have a history of cancer.My brain metastases are stable, and I haven't needed steroids in the last 14 days.My cancer has worsened after treatment, or I can't tolerate/choose not to have standard treatment.My CD4+ T-cell count is 350 or higher.I have lung inflammation not caused by an infection or a history of lung tissue disease.I am on antiviral therapy for my active chronic HBV before starting cancer treatment.I have stable Hepatitis C and my cancer treatment won't worsen it.I have gastric or gastroesophageal cancer and have been treated with chemotherapy, immune therapy, and possibly HER2 or other targeted therapy.My NSCLC progressed despite EGFR TKIs, or I've had anti-PD1 and platinum-based treatments for cMET alterations.
Research Study Groups:
This trial has the following groups:- Group 1: Part 1 Cohort 0
- Group 2: Part 1 Cohort 1
- Group 3: Part 1 Cohort 2
- Group 4: Part 1 Cohort 3
- Group 5: Part 1 Cohort 4
- Group 6: Part 1 Cohort 5
- Group 7: Part 2 Cohorts
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What potential hazards do people face with this treatment?
"Given the Phase 1 status of this trial, our internal analysis at Power has graded its safety with a score of 1. This is due to little evidence on both efficacy and security at present."
Answered by AI
Is enrollment for this research available to participants right now?
"Evidently, the trial is still recruiting according to clinicaltrials.gov records which show that it was originally posted on 8 May 2023 and last amended 9 of the same month."
Answered by AI
How many subjects are involved in this clinical experimentation?
"Affirmative. According to clinicaltrials.gov, this research venture is presently looking for participants, with the study having first been posted on May 8th 2023 and last updated on May 9th 2023. This trial requires 50 individuals from a single medical facility."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger